Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133939) titled 'A Single-Arm, Phase II Clinical Study of Ivonescimab Combined with Chemotherapy for the Induction Treatment of Locally Advanced Thymic Carcinoma' on Oct. 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanghai East Hospital
Condition:
Thymic carcinoma
Intervention:
Induction therapy group:Ivonescimab combined with chemotherapy:
1. Induction therapy regimen: Each 3-week period constitutes one dosing cycle, with administration on Day 1 of each cycle, for a total of 3 cycles of induction therapy.
(1)Ivonescimab: 20 mg/kg, D1, Q3W, intravenous infusion.
(2)Chemotherapy regimen: C...